Send me a link:

*Text messaging rates may apply.

 Dow Down0.36% Nasdaq Up0.23%

Halozyme Therapeutics, Inc. (HALO)

-NasdaqGS
9.44 Down 0.07(0.76%) 11:17AM EDT - Nasdaq Real Time Price
Income StatementGet Income Statement for:
View: Annual Data | Quarterly DataAll numbers in thousands
Period EndingMar 31, 2014Dec 31, 2013Sep 30, 2013Jun 30, 2013
Total Revenue 11,966   12,499   16,013   14,453  
Cost of Revenue5,520  3,540  683  1,284  
Gross Profit 6,446   8,959   15,330   13,169  
Operating Expenses
Research Development21,415  20,925  25,689  27,991  
Selling General and Administrative10,250  9,357  8,135  7,300  
Non Recurring -   -   -   -  
Others -   -   -   -  
Total Operating Expenses -   -   -   -  
Operating Income or Loss (25,219) (21,323) (18,494) (22,121)
Income from Continuing Operations
Total Other Income/Expenses Net47  65  51  58  
Earnings Before Interest And Taxes(25,172)(21,259)(18,442)(22,063)
Interest Expense1,376  728  850  849  
Income Before Tax(26,548)(21,986)(19,292)(22,912)
Income Tax Expense -   -   -   -  
Minority Interest -   -   -   -  
Net Income From Continuing Ops(26,548)(21,986)(19,292)(22,912)
Non-recurring Events
Discontinued Operations -   -   -   -  
Extraordinary Items -   -   -   -  
Effect Of Accounting Changes -   -   -   -  
Other Items -   -   -   -  
Net Income (26,548) (21,986) (19,292) (22,912)
Preferred Stock And Other Adjustments -   -   -   -  
Net Income Applicable To Common Shares (26,548) (21,986) (19,292) (22,912)

Sign Up for a Free Trial to EDGAR Online Premium!
Get the critical business and financial information you need for more than 15,000 U.S. public companies.
Sign Up Now - Learn More

Currency in USD.